The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Spectrum Pharmaceuticals Inc

Nasdaq: SPPI
Last

(U.S.) $7.38

Today's change0.00 0.00%
Updated November 28 9:37 AM EST. Delayed by at least 15 minutes.
 

Spectrum Pharmaceuticals Inc

Nasdaq: SPPI
Last

(U.S.) $7.38

Today's change0.00 0.00%
Updated November 28 9:37 AM EST. Delayed by at least 15 minutes.

Spectrum Pharmaceuticals Inc down slightly

Spectrum Pharmaceuticals Inc is down just (U.S.)$0.00 today to (U.S.)$7.38. Over the last five days, shares have gained 1.79%, but are down 16.61% for the last year to date. Shares have underperformed the S&P 500 by 37.54% during the last year.

Key company metrics

  • Open(U.S.) $7.41
  • Previous close(U.S.) $7.38
  • High(U.S.) $7.41
  • Low(U.S.) $7.33
  • Bid / Ask(U.S.) $7.35 / (U.S.) $7.39
  • YTD % change-16.61%
  • Volume12,247
  • Average volume (10-day)460,921
  • Average volume (1-month)613,462
  • Average volume (3-month)735,314
  • 52-week range(U.S.) $6.36 to (U.S.) $10.32
  • Beta1.84
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.30
Updated November 28 9:37 AM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-46.53%

Spectrum Pharmaceuticals Inc has a net profit margin of -46.53%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.53%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue48474042
Total other revenue--------
Total revenue48474042
Gross profit41413435
Total cost of revenue7666
Total operating expense52486548
Selling / general / administrative24252324
Research & development14112911
Depreciation / amortization7555
Interest expense (income), net operating--------
Unusual expense (income)------2
Other operating expenses, total--------
Operating income-4-1-24-7
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-8-5-28-4
Income after tax-12-4-28-39
Income tax, total3-1036
Net income-12-4-28-39
Total adjustments to net income--------
Net income before extra. items-12-4-28-39
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-12-4-28-39
Inc. avail. to common incl. extra. items-12-4-28-39
Diluted net income-12-4-28-39
Dilution adjustment00--0
Diluted weighted average shares65656363
Diluted EPS excluding extraordinary itemsvalue per share-0.18-0.06-0.44-0.63
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.18-0.06-0.44-0.61